Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 185
2021 1636
2022 682
2023 137
2024 1009

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,367 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 vaccine development: milestones, lessons and prospects.
Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. Li M, et al. Signal Transduct Target Ther. 2022 May 3;7(1):146. doi: 10.1038/s41392-022-00996-y. Signal Transduct Target Ther. 2022. PMID: 35504917 Free PMC article. Review.
COVID-19 vaccines in pregnancy.
Nunes MC, Madhi SA. Nunes MC, et al. Trends Mol Med. 2022 Aug;28(8):662-680. doi: 10.1016/j.molmed.2022.04.012. Epub 2022 May 3. Trends Mol Med. 2022. PMID: 35610123 Free PMC article. Review.
[Comment] COVID‑19 vaccine safety.
Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. Kostoff RN, et al. Int J Mol Med. 2020 Nov;46(5):1599-1602. doi: 10.3892/ijmm.2020.4733. Epub 2020 Sep 18. Int J Mol Med. 2020. PMID: 33000193 Free PMC article.
Structure of SARS-CoV-2 spike protein.
Zhang J, Xiao T, Cai Y, Chen B. Zhang J, et al. Curr Opin Virol. 2021 Oct;50:173-182. doi: 10.1016/j.coviro.2021.08.010. Epub 2021 Sep 8. Curr Opin Virol. 2021. PMID: 34534731 Free PMC article. Review.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
3,367 results